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The identification of malnutrition‑inflammation‑complex (MIC) and functional status (FS) is key 
to improving patient experience on hemodialysis (HD). We investigate the association of MIC and 
FS combinations with mortality in HD patients. We analyzed data from 5630 HD patients from 9 
countries in DOPPS phases 4–5 (2009–2015) with a median follow‑up of 23 [IQR 11, 31] months. MIC 
was defined as serum albumin < 3.8 g/dL and serum C‑reactive protein > 3 mg/L in Japan and > 10 mg/L 
elsewhere. FS score was defined as the sum of scores from the Katz Index of Independence in Activities 
of Daily Living and the Lawton‑Brody Instrumental Activities of Daily Living Scale. We investigated the 
association between combinations of MIC (+/−) and FS (low [< 11]/high [≥ 11]) with death. Compared 
to the reference group (MIC−/high FS), the adjusted hazard ratios [HR (95% CI)] for all‑cause mortality 
were 1.82 (1.49, 2.21) for MIC−/low FS, 1.57 (1.30, 1.89) for MIC+/high FS, and 3.44 (2.80, 4.23) for 
MIC+/low FS groups. Similar associations were observed with CVD‑related and infection‑related 
mortality. The combination of MIC and low FS is a strong predictor of mortality in HD patients. 
Identification of MIC and poor FS may direct interventions to lessen adverse clinical outcomes in the 
HD setting.
The association between measures of protein-energy malnutrition and inflammation in dialysis patients with 
adverse outcomes is  strong1–3. Furthermore, it is common for these two conditions to occur concomitantly. 
Due to these circumstances, researchers have often used the term malnutrition-inflammation complex (MIC) 
to designate the combination of the two conditions in this  population4. Known risk factors for mortality in the 
general population (e.g., high BMI, high total serum cholesterol) are less frequent in MIC patients and yet they 
have higher risk of death due to their pro-inflammatory  state1.
MIC is also associated with decreased body stores of protein and energy  fuels5,6, affecting up to half of hemo-
dialysis (HD)  patients7 and ultimately leading to sarcopenia and  frailty5,6,8. The initiation of HD is also associ-
ated with a decline in functional status (FS) in the  elderly9, leading to a vicious cycle of reduced food intake, 
due to decreased physical function and lack of appetite, resulting in worsened nutritional  status1. The Dialysis 
Outcomes and Practice Patterns Study (DOPPS) showed that low activities of daily living (ADL) is associated 
with mortality in hemodialysis  patients10.
Several national and international guidelines recommend both nutritional and physical therapy for dialysis 
patients to improve their experience and  outcomes11–13. Prevention through early identification of patients with 
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MIC, along with the appropriate therapeutic interventions, are important actions to consider in order to improve 
the patient experience on  HD6,14,15.
In this study, we explore the combined effects of MIC and FS on mortality in HD patients.
Results
There were 15,266 patients enrolled in DOPPS phases 4 and 5 from facilities that collected CRP routinely in 
Japan, Europe, and Australia/New Zealand. We excluded patients from facilities that did not often collect albumin 
(N = 1707). We also excluded patients who did not return a PQ (N = 2968) and those who did not complete the 
FS assessment (N = 393). Among eligible facilities, we also excluded patients who did not have albumin and/or 
CRP levels measured at study baseline (N = 500). Our study population consisted of 5630 HD patients with a 
median follow-up of 23 [IQR 11, 31] months (see STROBE diagram, Fig. 1). Japanese clinics accounted for 42% 
of patients in our sample, European clinics for 53% and clinics from Australia/New Zealand for 5%. There were 
869 deaths over the follow-up period (crude death rate = 8.9 per 100 patient-years), 301 deaths reported with 
a CV cause (3.1 per 100 patient-years), and 136 deaths due to an infectious cause (1.4 per 100 patient-years).
High CRP was present in 27% of the population (Table 1), ranging from 23% in Japan to 39% in the UK. 
Low albumin was present in 53% of patients and varied by country: 39% in Spanish patients and as high as 74% 
of patients in Sweden. MIC was present in 19%, and low FS was observed in 33% of our sample (Table 2). The 
prevalence of the combinations of MIC (+/−) and FS (low/high) by country is shown in Fig. 2. Japan had the 
highest prevalence (68%) of patients without any conditions (MIC−/high FS), whereas the prevalence of both 
(MIC+/low FS) was highest in the UK (17%).
Figure 1.  STROBE diagram of the study sample. ADL, activities of daily living; CRP, C-reactive protein.
Table 1.  Percentage of the patients with MIC. Proportions (%) calculated with the total (N = 5630) as the 
denominator. High serum CRP level was defined as greater than 3 mg/L in Japan and 10 mg/L in other DOPPS 
countries. MIC, malnutrition-inflammation-complex; CRP, C-reactive protein.
CRP categories
Albumin categories
 < 3.8 g/dL  ≥ 3.8 g/dL Total
Low CRP 1915 (34%) 2200 (39%) 4213 (73%)
High CRP 1054 (19%) 461 (8%) 1558 (27%)
Total 2969 (53%) 2661 (47%) 5630
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Patient characteristics by MIC and FS combinations are shown in Table 3. Patients in the MIC−/high FS group 
were much younger (61.1 vs. 71.2), and had lower prevalence of comorbid conditions compared to patients with 
MIC+ and low FS. The prevalence of heart disease comorbidities was higher in patients who had the combina-
tion of MIC+ and low FS, as coronary artery disease was present in 46% of patients with MIC+/low FS and only 
25% of patients with MIC−/high FS. Moreover, the prevalence of heart failure was higher in patients with MIC+/
low FS (28%) than MIC−/high FS (16%). MIC+/low FS patients also had lower mean creatinine (7.2 mg/dL vs. 
9.9 mg/dL), phosphorus values (4.7 vs. 5.2 mg/dL), and a greater use of catheter as vascular access for HD (30% 
vs. 11%) than MIC−/high FS.
As individual predictors, MIC+ and low FS were each associated with an increased risk of death (HR for 
MIC+: 2.11 [1.84, 2.42]; HR for low FS: 1.76 [1.50, 2.07]). There was no interaction between MIC and low FS in 
the association with mortality (p for interaction = 0.40). Estimated effects of MIC/FS combinations on all-cause 
mortality are provided by level of covariate adjustment in Table 4. The unadjusted associations were very strong 
(Model 1), and remained robust after adjustment for possible confounders (Model 4). The adjusted hazard ratios 
(95% CI) for all-cause mortality, compared to the reference group of MIC−/high FS were 1.82 (1.49, 2.21) for 
MIC−/low FS, 1.57 (1.30, 1.89) for MIC+/high FS, and 3.44 (2.80, 4.23) for MIC+/ low FS.
The cause-specific analysis for CV and infectious mortality followed a similar pattern of association (Table 5), 
with MIC−/high FS patients having the lowest risk and patients with MIC+/low FS with a nearly four-fold risk 
for infection-related (HR: 3.91 [2.35, 6.51]) and for CVD-related mortality (HR: 3.97 [2.71, 5.83]). There were 
no interactions of MIC and FS for CV or infectious mortality (p for interaction = 0.10 and 0.19 for CV and infec-
tious mortality, respectively).
Discussion
This analysis of international DOPPS data shows that MIC in combination with low FS is associated with a high 
risk of death in HD patients. The presence of one of the components increases the risk by 56% (low FS only) 
to 75% (MIC+ only). The presence of both conditions results in a more than three-fold higher rate of all-cause 
mortality, and a nearly four-fold higher rate of CVD- and infection-related death. To the best of our knowledge, 
this is the first study reporting the combined impact of MIC and low FS in HD patients.
Although there was higher prevalence of diabetes, CVD, and cancer in the MIC+/low FS group, the higher 
risk of all-cause and cause-specific death persisted even after extensive adjustment for these and other risk 
factors. Previous observational studies indicated that the inverse association between serum cholesterol and 
Table 2.  Distribution of functional status (FS) categories and MIC in the study population. Proportions 
(%) calculated with the total (N = 5630) as the denominator. Low FS defined as the sum of scores from the 
self-reported limitations in the Katz Index of Independence in Activities of Daily Living (range 0–5) and the 
Lawton-Brody Instrumental Activities of Daily Living Scale (range 0–8) less than 11. MIC, malnutrition-
inflammation-complex; FS, functional status.
FS categories N (%) MIC categories N (%)
High FS 3774 (67%) MIC− 4576 (81%)
Low FS 1856 (33%) MIC+ 1054 (19%)
Total 5630 Total 5630
Figure 2.  Distribution of MIC and FS combinations by country. MIC, malnutrition-inflammation-complex; 
FS, functional status; A/NZ, Australia/ New Zealand; Bel, Belgium; Fra, France; Ita, Italy; Jpn, Japan; Spa, Spain; 
Swe, Sweden; UK, United Kingdom.
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mortality in HD patients, paradoxical in comparison to the general population, is likely due to malnutrition 
and  inflammation5,16. These lines of evidence suggest that malnutrition and systemic inflammation may play 
important roles in increasing the risk of death in HD patients.
The MIC+/low FS patients had lower mean serum creatinine and phosphorus levels, indicating low muscle 
mass and protein intake which, along with low FS, represent risk factors for death in dialysis  patients17. Interven-
tions to improve nutritional status also improve inflammation, as well as physical performance. A randomized 
controlled trial (RCT) in which HD patients received oral supplementation with a whey protein, soy protein, or 
Table 3.  Patient characteristics according to combined MIC/FS categories. Values are shown as average 
(standard deviation). MIC, malnutrition-inflammation-complex; FS, functional status; BMI, body mass index; 
GI, gastrointestinal; CRP, C-reactive protein; IQR, interquartile range; WBC, white blood cell count.
Patient characteristics MIC−/high FS MIC+/high FS MIC−/low FS MIC+/low FS
Patients, n (row %) 3259 (58%) 515 (9%) 1317 (23%) 539 (10%)
Demographics
Age (years) 61.1 (13.8) 65.1 (12.4) 71.2 (11.9) 71.2 (11.5)
Male (%) 64% 70% 56% 62%
Body Mass index (kg/m2) 23.7 (5.1) 24.2 (5.8) 24.6 (5.5) 25.1 (6.7)
Median time on dialysis [IQR] (years) 3.1 [0.9, 8.3] 3.2 [0.8, 7.9] 2.8 [0.9, 6.3] 2.7 [0.8, 6.8]
Urine volume > 200 ml 35% 28% 30% 27%
Comorbidities
Diabetes (%) 31% 36% 49% 47%
Hypertension (%) 85% 85% 83% 79%
Coronary artery disease (%) 26% 36% 43% 45%
Congestive heart failure (%) 16% 22% 28% 28%
Other heart disease (%) 24% 32% 38% 40%
Cerebrovascular disease (%) 9% 12% 24% 22%
Cancer (%) 13% 16% 16% 21%
Psychiatric disorder (%) 10% 13% 16% 19%
Peripheral vascular disease (%) 16% 26% 36% 44%
Recurrent cellulitis (%) 4% 6% 12% 18%
Lung disease (%) 7% 12% 13% 17%
Laboratory
Median CRP [IQR] (mg/L) 1.9 [0.7, 5.0] 15.0 [10.0, 28.5] 3.1 [1.0, 6.1] 21.0 (12.0, 39.6)
WBC (1000*cells/mm3) 6.3 (2.0) 7.2 (2.51) 6.5 (2.1) 7.4 (2.8)
Albumin (g/dL) 3.84 (0.40) 3.35 (0.33) 3.70 (0.43) 3.19 (0.42)
Hemoglobin (g/dL) 11.2 (1.3) 10.8 (1.4) 11.2 (1.3) 10.8 (1.5)
Creatinine (mg/dL) 9.9 (3.0) 8.8 (2.7) 7.8 (2.5) 7.2 (2.3)
Phosphorus (mg/dL) 5.2 (1.5) 5.1 (1.6) 4.8 (1.4) 4.7 (1.6)
Total calcium (mg/dL) 9.0 (0.7) 8.8 (0.7) 9.0 (0.7) 8.8 (0.8)
Vascular access
Catheter use (%) 11% 17% 26% 30%
Table 4.  Association of MIC and FS status combinations on risk of death, by level of adjustment. Crude 
death rate was 8.9 per 100 patient-years (N = 869 deaths). The association of MIC and FS status with risk of 
death was evaluated using Cox proportional hazards models adjusted for baseline characteristics. The models 
were defined by the covariates added to the model, as follows: Model 1: stratified by country and phase of the 
study. Model 2: Adjusted for age, sex, and body mass index. Model 3: Model 2 adjustments, plus comorbidity 
history, and catheter use. Model 4: Model 3 adjustments, plus serum creatinine and phosphorus levels, WBC 
count, hemoglobin level, and vintage (main model). Values are hazard ratios (95% confidence interval). MIC, 
malnutrition-inflammation-complex; FS, functional status.
N (%) Model 1 Model 2 Model 3 Model 4
MIC−/high FS 3259 (58) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
MIC−/low FS 515 (9) 2.81 (2.33, 3.38) 2.20 (1.81, 2.68) 2.07 (1.70, 2.52) 1.82 (1.49, 2.21)
MIC+/high FS 1317 (23) 2.54 (2.07, 3.13) 2.04 (1.69, 2.46) 1.71 (1.41, 2.08) 1.57 (1.30, 1.89)
MIC+/low FS 539 (10) 6.98 (5.74, 8.49) 5.25 (4.34, 6.35) 4.27 (3.48, 5.24) 3.44 (2.80, 4.23)
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placebo beverage for 6 months before each HD session showed that protein supplementation reduced predialysis 
interleukin 6 levels and CRP, with gait speed and shuttle walk test improvement observed, as  well18. An obser-
vational study of an oral nutritional supplement prescription for patients with albumin ≤ 3.5 g/dL during HD 
showed an association with reduced mortality despite no change in serum albumin  levels19. In our study, patients 
with both MIC+ and low FS had a much greater risk of death due to CV and infection causes than patients with 
only 1 of the 2 exposures, which is suggestive of a potential biological interaction in the CKD setting.
A systematic review and meta-analysis suggested that physical exercise, including during the HD session, 
improves physical functioning, cardiovascular fitness, health related quality of life, oxygen uptake (VO2-max), 
and dialysis adequacy (KT/V) in HD  patients20. Furthermore, protein anabolism is enhanced by resistance 
training before HD and nutrition intake during  dialysis21. A RCT showed that a 6-min walking exercise on a 
treadmill during a dialysis session combined with nutritional supplements is a feasible and well accepted strategy 
that improves physical function and quality of  life22. Therefore, the combined use of nutritional intervention and 
exercise training may be effective in improving prognosis of MIC and low FS in HD patients such as the ones 
participating in this study. The Japanese Society of Renal Rehabilitation, as well as other international guidelines, 
highlight the importance of both nutritional therapy and exercise interventions for patients with  PEW11.
DOPPS has shown differences in the mortality rates and practice patterns that affect HD patients’ outcomes 
between the participating  countries23. For instance, the first-year mortality rate in Belgium is greater than in Japan 
or the United  Kingdom23. Our study showed that MIC+/low FS is an independent risk factor for death and was 
less prevalent in Japan compared to other countries, which might in part explain the lower mortality in Japanese 
HD patients. On the other hand, similar distributions of MIC+/low FS were found in the United Kingdom and 
Belgium. DOPPS has also shown that dialysis catheter use is preferred by patients in Belgium, and the rate of 
catheter use is higher in Belgium than in other  countries24. The use of catheters for vascular access in HD is 
associated with malnutrition and inflammation, as well as a higher risk of  death25. Thus, HD-related factors other 
than MIC+/low FS, such as catheter use, might lead to the difference in mortality across DOPPS countries. How-
ever, this analysis was adjusted for catheter use, although residual confounding cannot be completely excluded.
This study has some limitations. Although causal inference cannot be made due to the observational nature 
of this study, this analysis may be adequate in accomplishing its objective of showing a higher risk of death 
associated with having these nutritional and inflammation risk factors. We also acknowledge the potential for 
misclassification of causes of death, which may bias the estimated associations with CVD and infection-related 
mortality. A clinical trial on MIC/low FS would demand an elaborate intervention that may not have an impact 
on the outcomes. The use of real-world data from a great number of in-center hemodialysis center patients and 
standardized protocol for data collection are important strengths of this study. Given the random sampling design 
of the DOPPS, our study sample can be viewed as representative of the HD population in each participating 
country, and the large sample size provided sufficient statistical power to detect the proposed  associations26. 
Third, nutrition intake is influenced by food. However, because DOPPS data does not include diet record, we 
could not evaluate the effects of diet on nutritional status. Fourth, Kanda E. et al. showed the importance and 
the cutoff levels of serum creatinine levels as a nutritional index using a database of the Japanese Society for 
Dialysis  Therapy8. However, it was difficult to use serum creatinine levels for the categorization of MIC, because 
three indices might categorize patients into many groups and complicate study design. A simple and accurate 
index for malnutrition is one of the important themes to improve nutritional conditions of dialysis patients.
Conclusion
This study demonstrates that the combination of MIC and low FS is associated with a higher risk of both all-cause 
and cause-specific deaths in HD patients. This suggests that the diagnosis of malnourishment and inflammation 
with albumin and CRP, as well as FS, may be useful for risk stratification for survival in these patients. We believe 
that this approach will direct attention to nutritional and exercise interventions, based on simple and objective 
measures, to improve experience and outcomes of patients receiving HD.
Materials and methods
Data source. DOPPS is a prospective cohort study, ongoing since 1996, involving center-based adult chronic 
HD patients in more than 20 countries. Study sites and patients are randomly selected to achieve national sam-
ples. Detail on the study design is included in previous  publications16,27 and at http://www.DOPPS .org. DOPPS 
Table 5.  Combined effects of MIC and FS status on risk of cause-specific death. The association of MIC and 
FS status with risk of cause-specific death was evaluated using Cox proportional hazards with models adjusted 
with same covariates as model 3 in Table 4. Results are shown as hazard ratio (95% confidence interval). 
Infection related death rate was 1.4/100 patient-years (total of 136 deaths) and CVD-related death rate was 
3.1/100 patient-years (total of 301 deaths), respectively. MIC, malnutrition-inflammation-complex; FS, 
functional status.
Infection-related mortality CVD-related mortality
MIC−/high FS 1 (ref) 1 (ref)
MIC−/low FS 1.52 (0.83, 2.79) 1.59 (1.06, 2.38)
MIC+/high FS 1.53 (0.91, 2.56) 1.49 (1.07, 2.06)
MIC+/low FS 3.91 (2.35, 6.51) 3.97 (2.71, 5.83)
6
Vol:.(1234567890)
Scientific Reports |         (2021) 11:1582  | https://doi.org/10.1038/s41598-020-80716-0
www.nature.com/scientificreports/
maintains institutional review board or ethical committee approvals in all participating countries, and informed 
consent is collected from patients selected for study participation. This work included a cohort of HD patients 
from Australia, France, Germany, Italy, Japan, New Zealand, Spain, Sweden, and the United Kingdom, enrolled 
in DOPPS phases 4 (2009–2011) and 5 (2012–2015).
Measures. We defined MIC by the presence of both low albumin and high C-reactive protein (CRP) levels. 
We considered low albumin as serum albumin levels < 3.8 g/dL. Because CRP levels are systematically lower in 
Japan, two thresholds for high CRP level were defined: > 3 mg/L in Japan and > 10 mg/L  elsewhere28. The distri-
bution of CRP > 3 mg/L in Japan is still lower (prevalence of 23%) than the prevalence of CRP > 10 mg/L in other 
DOPPS countries (prevalence ranges from 24% in Italy to 39% in the UK).
FS was assessed by the DOPPS self-reported patient questionnaire (PQ), and details were described in the 
previous  study10. In brief, patients indicated their level of ability to perform five activities of daily living tasks 
(Katz questionnaire: eating, getting dressed, bathing, using the toilet, transferring from bed to chair) and eight 
instrumental activities of daily living tasks (Brody questionnaire: using the telephone, getting to places beyond 
walking distance, grocery shopping, preparing meals, doing housework or handyman work, doing laundry, taking 
medications, and managing money)29,30. Both questionnaires have been validated in the general population. Low 
FS was defined by a FS score of < 11 out of the 13-points of the combined Katz and Brody scales, calculated as in 
Jassal et al.10 on which a score of 13 represents full functional independence. Time-to-event outcomes included 
all-cause mortality (primary) and cause-specific death (secondary) due to (1) CVD or (2) infection. We explored 
both the main effects and the combined effect between the two exposure variables on mortality.
Patient/study sample. Patients were included if they answered all 13 FS questions on the PQ and had 
available data on serum albumin and CRP in the three months before PQ completion. We limited our sample 
to facilities that routinely measured CRP and albumin levels in over half of their patients to limit cases where 
they were measured “by indication”. We excluded patients with a prior history of limb amputation to accurately 
evaluate BMI.
Statistical analyses. Cox proportional hazards models were used to analyze the association of the combi-
nations of MIC (+/−) and FS (low/high) with mortality, stratified by country and DOPPS phase, and accounting 
for facility clustering using robust sandwich covariance estimators. Models were adjusted for case-mix (patient 
characteristics: age, sex, body mass index, vintage, and comorbid history of diabetes mellitus, hypertension, 
coronary artery disease, congestive heart failure, other heart diseases, cerebrovascular disease, cancer, gastroin-
testinal bleeding, psychiatric disorder, peripheral vascular disease, recurrent cellulitis, and lung disease), central 
venous catheter use, and laboratory values (serum creatinine and phosphorus levels, white blood cell count 
[WBC], and hemoglobin level). Time at risk started at the completion of the PQ and ended at the time of death, 
7 days after leaving the facility due to transplant or transfer, 7 days after changing modality, loss to follow-up, or 
administrative study end. The proportional hazards assumption was confirmed. Additionally, cause-specific Cox 
models were used to test the association of MIC and/or FS with cause-specific (infection, CVD-related) mortal-
ity. Deaths by other causes were censored in this approach.
Overall, missingness for covariates was low (< 20% for the majority of covariates). For missing data, we used 
the sequential regression multiple imputation method implemented by  IVEware31, and the MIAnalyze proce-
dure in SAS/STAT 9.4. All analyses were carried out using SAS software, version 9.4 (SAS institute, Cary, NC).
Data availability
The data that support the findings of this study are available from Arbor Research Collaborative for Health, but 
restrictions apply to the availability of these data which were used for the current study, and so are not publicly 
available. Data are however available from the authors upon reasonable request and with permission of Arbor 
Research Collaborative for Health.
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